Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/study/NCT06241118
Registration number
NCT06241118
Ethics application status
Date submitted
26/01/2024
Date registered
5/02/2024
Date last updated
19/06/2025
Titles & IDs
Public title
A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab on Background Topical Corticosteroids Therapy in Participants Aged 12 Years and Older With Moderate-to-severe AD Who Have Had an Inadequate Response to Prior Biologic Therapy or an Oral JAK Inhibitor
Query!
Scientific title
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis (AD) Who Are on Background Topical Corticosteroids and Have Had an Inadequate Response to Prior Biologic Therapy or Oral Janus Kinase (JAK) Inhibitor Treatment
Query!
Secondary ID [1]
0
0
2023-508099-12
Query!
Secondary ID [2]
0
0
EFC17599
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
AQUA
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Dermatitis Atopic
0
0
Query!
Condition category
Condition code
Skin
0
0
0
0
Query!
Dermatological conditions
Query!
Skin
0
0
0
0
Query!
Other skin conditions
Query!
Inflammatory and Immune System
0
0
0
0
Query!
Other inflammatory or immune system disorders
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Amlitelimab
Treatment: Drugs - Placebo
Treatment: Drugs - Topical corticosteroids
Treatment: Drugs - Topical tacrolimus or pimecrolimus
Experimental: Amlitelimab dose 1 - Subcutaneous injection as per protocol
Experimental: Amlitelimab dose 2 - Subcutaneous injection as per protocol
Placebo comparator: Placebo - Subcutaneous injection as per protocol
Treatment: Drugs: Amlitelimab
Pharmaceutical form: Injection solution Route of administration: Subcutaneous
Treatment: Drugs: Placebo
Pharmaceutical form: Injection solution Route of administration: Subcutaneous
Treatment: Drugs: Topical corticosteroids
Pharmaceutical form: Various Topical formulation Route of administration: Topical
Treatment: Drugs: Topical tacrolimus or pimecrolimus
Pharmaceutical form: Various Topical formulation Route of administration: Topical
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
EU, EU reference countries, and Japan: Proportion of participants with Validated Investigator Global Assessment scale for Atopic Dermatitis (vIGA-AD) of 0 (clear) or 1 (almost clear) and a reduction from baseline of =2 points at Week 36
Query!
Assessment method [1]
0
0
The vIGA-AD is an Investigator-completed assessment scale used to determine severity of AD and clinical response to treatment. It is based on a 5-point scale, ranging from 0 (clear) to 4 (severe).
Query!
Timepoint [1]
0
0
Week 36
Query!
Primary outcome [2]
0
0
EU, EU reference countries, and Japan: Proportion of participants reaching 75% reduction from baseline in Eczema Area and Severity Index (EASI) score (EASI75) at Week 36
Query!
Assessment method [2]
0
0
The EASI is an Investigator-assessed validated tool used to measure the extent (area) and severity of AD. Total score ranges from 0 to 72 with a higher score indicating increased extent and severity of AD.
Query!
Timepoint [2]
0
0
Week 36
Query!
Primary outcome [3]
0
0
US and US reference countries: Proportion of participants with vIGA-AD of 0 (clear) or 1 (almost clear) and a reduction from baseline of =2 points at Week 36
Query!
Assessment method [3]
0
0
The vIGA-AD is an Investigator-completed assessment scale used to determine severity of AD and clinical response to treatment. It is based on a 5-point scale, ranging from 0 (clear) to 4 (severe).
Query!
Timepoint [3]
0
0
Week 36
Query!
Secondary outcome [1]
0
0
Proportion of participants reaching EASI-75 at Week 36 (for US and US reference countries only)
Query!
Assessment method [1]
0
0
The EASI is an Investigator-assessed validated tool used to measure the extent (area) and severity of AD. Total score ranges from 0 to 72 with a higher score indicating increased extent and severity of AD. EASI-75 is 75% reduction from baseline in EASI score.
Query!
Timepoint [1]
0
0
Week 36
Query!
Secondary outcome [2]
0
0
Proportion of participants with vIGA-AD 0 (clear) or 1 (almost clear) with presence of only barely perceptible erythema (no induration/papulation, no lichenification, no oozing or crusting and a reduction from baseline of =2 points)
Query!
Assessment method [2]
0
0
The vIGA-AD is an Investigator-completed assessment scale used to determine severity of AD and clinical response to treatment. It is based on a 5-point scale, ranging from 0 (clear) to 4 (severe).
Query!
Timepoint [2]
0
0
Baseline to Week 36
Query!
Secondary outcome [3]
0
0
Proportion of participants with =4-point reduction in weekly average of daily Peak Pruritus-Numerical Rating Scale (PP-NRS) from baseline in participants with baseline weekly average of daily PP-NRS =4
Query!
Assessment method [3]
0
0
The PP-NRS is a validated single item 0-10 numeric rating scale assessing peak pruritus (itch) associated with AD with 0 = no itch and 10 = worst itch imaginable.
Query!
Timepoint [3]
0
0
Baseline to Week 36
Query!
Secondary outcome [4]
0
0
Proportion of participants reaching EASI-75
Query!
Assessment method [4]
0
0
The EASI is an Investigator-assessed validated tool used to measure the extent (area) and severity of AD. Total score ranges from 0 to 72 with a higher score indicating increased extent and severity of AD. EASI-75 is 75% reduction from baseline in EASI score.
Query!
Timepoint [4]
0
0
Baseline to Week 24
Query!
Secondary outcome [5]
0
0
Proportion of participants with vIGA-AD of 0 (clear) or 1 (almost clear) and a reduction from baseline of =2 points
Query!
Assessment method [5]
0
0
The vIGA-AD is an Investigator-completed assessment scale used to determine severity of AD and clinical response to treatment. It is based on a 5-point scale, ranging from 0 (clear) to 4 (severe).
Query!
Timepoint [5]
0
0
Baseline to Week 24
Query!
Secondary outcome [6]
0
0
Proportion of participants reaching EASI-90
Query!
Assessment method [6]
0
0
The EASI is an Investigator-assessed validated tool used to measure the extent (area) and severity of AD. Total score ranges from 0 to 72 with a higher score indicating increased extent and severity of AD. EASI-90 is 90% reduction from baseline in EASI score.
Query!
Timepoint [6]
0
0
Baseline to Week 36
Query!
Secondary outcome [7]
0
0
Proportion of participants reaching EASI-100
Query!
Assessment method [7]
0
0
The EASI is an Investigator-assessed validated tool used to measure the extent (area) and severity of AD. Total score ranges from 0 to 72 with a higher score indicating increased extent and severity of AD. EASI-100 is 100% reduction from baseline in EASI score.
Query!
Timepoint [7]
0
0
Baseline to Week 36
Query!
Secondary outcome [8]
0
0
Proportion of participants with PP-NRS 0 or 1
Query!
Assessment method [8]
0
0
The PP-NRS is a validated single item 0-10 numeric rating scale assessing peak pruritus (itch) associated with AD with 0 = no itch and 10 = worst itch imaginable.
Query!
Timepoint [8]
0
0
Baseline to Week 36
Query!
Secondary outcome [9]
0
0
Change in Dermatology Life Quality Index (DLQI) from baseline in participants with age =16 years old
Query!
Assessment method [9]
0
0
The DLQI is a validated 10-item questionnaire to measure dermatology-specific quality of life (QoL) in adult patients. Overall scoring ranges from 0 to 30, with a higher score indicating a poorer QoL.
Query!
Timepoint [9]
0
0
Baseline to Week 36
Query!
Secondary outcome [10]
0
0
Proportion of participants with a reduction in DLQI =4 from baseline in participants with age =16 years old and with DLQI baseline =4
Query!
Assessment method [10]
0
0
The DLQI is a validated 10-item questionnaire to measure dermatology-specific quality of life (QoL) in adult patients. Overall scoring ranges from 0 to 30, with a higher score indicating a poorer QoL.
Query!
Timepoint [10]
0
0
Baseline to Week 36
Query!
Secondary outcome [11]
0
0
Change in Children Dermatology Life Quality Index (CDLQI) from baseline in participants with age =12 to <16 years
Query!
Assessment method [11]
0
0
The CDLQI is a validated 10-item questionnaire to measure dermatology-specific quality of life (QoL) in children aged 4-\<16 years. Overall scoring ranges from 0 to 30, with a higher score indicating a poorer QoL.
Query!
Timepoint [11]
0
0
Baseline to Week 36
Query!
Secondary outcome [12]
0
0
Proportion of participants with a reduction in CDLQI =6 from baseline in participants with age =12 to <16 years old and with CDLQI baseline =6
Query!
Assessment method [12]
0
0
The CDLQI is a validated 10-item questionnaire to measure dermatology-specific quality of life (QoL) in children aged 4-\<16 years. Overall scoring ranges from 0 to 30, with a higher score indicating a poorer QoL.
Query!
Timepoint [12]
0
0
Baseline to Week 36
Query!
Secondary outcome [13]
0
0
Change in Hospital Anxiety Depression Scale (HADS) from baseline
Query!
Assessment method [13]
0
0
The HADS is 14-item questionnaire with two subscales: anxiety \& depression. Each subscale (anxiety \& depression) ranges 0-21. The total HADS score ranges 0-42 with higher score indicating a poorer state.
Query!
Timepoint [13]
0
0
Baseline to Week 36
Query!
Secondary outcome [14]
0
0
Proportion of participants with HADS subscale Anxiety (HADS-A) <8 in participants with baseline HADS-A =8
Query!
Assessment method [14]
0
0
HADS-A score ranges 0-21 with higher score indicating a poorer state.
Query!
Timepoint [14]
0
0
Baseline to Week 36
Query!
Secondary outcome [15]
0
0
Proportion of participants with HADS subscale Depression (HADS-D) <8 in participants with HADS-D baseline =8
Query!
Assessment method [15]
0
0
HADS-D score ranges 0-21 with higher score indicating a poorer state.
Query!
Timepoint [15]
0
0
Baseline to Week 36
Query!
Secondary outcome [16]
0
0
Absolute change in weekly average of daily Skin Pain-Numerical Rating Scale (SP-NRS) from baseline
Query!
Assessment method [16]
0
0
The SP-NRS is a single item 0-10 numeric rating scale assessing skin pain associated with AD with 0 = no pain and 10 = worst possible pain imaginable.
Query!
Timepoint [16]
0
0
Baseline to Week 36
Query!
Secondary outcome [17]
0
0
Proportion of participants with a reduction in weekly average of daily SP-NRS =4 from baseline in participants with baseline weekly average of daily SP-NRS =4
Query!
Assessment method [17]
0
0
The SP-NRS is a single item 0-10 numeric rating scale assessing skin pain associated with AD with 0 = no pain and 10 = worst possible pain imaginable.
Query!
Timepoint [17]
0
0
Baseline to Week 36
Query!
Secondary outcome [18]
0
0
Percent change in weekly average of daily SP-NRS from baseline
Query!
Assessment method [18]
0
0
The SP-NRS is a single item 0-10 numeric rating scale assessing skin pain associated with AD with 0 = no pain and 10 = worst possible pain imaginable.
Query!
Timepoint [18]
0
0
Baseline to Week 36
Query!
Secondary outcome [19]
0
0
Proportion of participants with vIGA-AD 0 (clear)
Query!
Assessment method [19]
0
0
The vIGA-AD is an Investigator-completed assessment scale used to determine severity of AD and clinical response to treatment. It is based on a 5-point scale, ranging from 0 (clear) to 4 (severe).
Query!
Timepoint [19]
0
0
Baseline to Week 36
Query!
Secondary outcome [20]
0
0
Absolute change in weekly average of daily Sleep Disturbance-Numerical Rating Scale (SD-NRS) from baseline
Query!
Assessment method [20]
0
0
The SD-NRS is a single item 0-10 numeric rating scale assessing sleep disturbance associated with AD with 0 = no sleep loss and 10 = did not sleep at all.
Query!
Timepoint [20]
0
0
Baseline to Week 36
Query!
Secondary outcome [21]
0
0
Proportion of participants with a reduction in weekly average of daily SD-NRS =3 from baseline in participants with Baseline weekly average of daily SD-NRS =3
Query!
Assessment method [21]
0
0
The SD-NRS is a single item 0-10 numeric rating scale assessing sleep disturbance associated with AD with 0 = no sleep loss and 10 = did not sleep at all.
Query!
Timepoint [21]
0
0
Baseline to Week 36
Query!
Secondary outcome [22]
0
0
Percent change in weekly average of daily SD-NRS
Query!
Assessment method [22]
0
0
The SD-NRS is a single item 0-10 numeric rating scale assessing sleep disturbance associated with AD with 0 = no sleep loss and 10 = did not sleep at all.
Query!
Timepoint [22]
0
0
Baseline to Week 36
Query!
Secondary outcome [23]
0
0
Percent change in EASI score from baseline
Query!
Assessment method [23]
0
0
The EASI is an Investigator-assessed validated tool used to measure the extent (area) and severity of AD. Total score ranges from 0 to 72 with a higher score indicating increased extent and severity of AD.
Query!
Timepoint [23]
0
0
Baseline to Week 36
Query!
Secondary outcome [24]
0
0
Percent change in weekly average of daily PP-NRS from baseline
Query!
Assessment method [24]
0
0
The PP-NRS is a validated single item 0-10 numeric rating scale assessing peak pruritus (itch) associated with AD with 0 = no itch and 10 = worst itch imaginable.
Query!
Timepoint [24]
0
0
Baseline to Week 36
Query!
Secondary outcome [25]
0
0
Absolute change in weekly average of daily PP-NRS from baseline
Query!
Assessment method [25]
0
0
The PP-NRS is a validated single item 0-10 numeric rating scale assessing peak pruritus (itch) associated with AD with 0 = no itch and 10 = worst itch imaginable.
Query!
Timepoint [25]
0
0
Baseline to Week 36
Query!
Secondary outcome [26]
0
0
Proportion of participants reaching EASI-50
Query!
Assessment method [26]
0
0
The EASI is an Investigator-assessed validated tool used to measure the extent (area) and severity of AD. Total score ranges from 0 to 72 with a higher score indicating increased extent and severity of AD. EASI-50 is 50% reduction from baseline in EASI score.
Query!
Timepoint [26]
0
0
Baseline to Week 36
Query!
Secondary outcome [27]
0
0
Proportion of participants with EASI =7
Query!
Assessment method [27]
0
0
The EASI is an Investigator-assessed validated tool used to measure the extent (area) and severity of AD. Total score ranges from 0 to 72 with a higher score indicating increased extent and severity of AD.
Query!
Timepoint [27]
0
0
Baseline to Week 36
Query!
Secondary outcome [28]
0
0
Change in percent Body Surface Area (BSA) affected by AD from baseline
Query!
Assessment method [28]
0
0
Query!
Timepoint [28]
0
0
Baseline to Week 36
Query!
Secondary outcome [29]
0
0
Percent change in Scoring Atopic Dermatitis (SCORAD) index from baseline
Query!
Assessment method [29]
0
0
The SCORAD index is a clinical tool to evaluate the extent and severity of AD. Total score ranges from 0 (absent disease) to 103 (severe disease).
Query!
Timepoint [29]
0
0
Baseline to Week 36
Query!
Secondary outcome [30]
0
0
Absolute change in SCORAD index from baseline
Query!
Assessment method [30]
0
0
The SCORAD index is a clinical tool to evaluate the extent and severity of AD. Total score ranges from 0 (absent disease) to 103 (severe disease).
Query!
Timepoint [30]
0
0
Baseline to Week 36
Query!
Secondary outcome [31]
0
0
Proportion of participants with a reduction in SCORAD = 8.7 points from baseline in participants with baseline SCORAD score = 8.7
Query!
Assessment method [31]
0
0
The SCORAD index is a clinical tool to evaluate the extent and severity of AD. Total score ranges from 0 (absent disease) to 103 (severe disease).
Query!
Timepoint [31]
0
0
Baseline to Week 36
Query!
Secondary outcome [32]
0
0
Proportion of participants with a reduction in Patient Oriented Eczema Measure (POEM) =4 from baseline in participants with POEM Baseline =4
Query!
Assessment method [32]
0
0
The POEM is a 7-item self-assessment questionnaire that assesses disease symptoms on a 5-point scale; 0 (no days) to 4 (every day in the last week). The sum of the 7 items gives the total POEM score of 0 (absent disease) to 28 (very severe). Higher scores indicated more severe disease and poor quality of life.
Query!
Timepoint [32]
0
0
Baseline to Week 36
Query!
Secondary outcome [33]
0
0
Change in POEM from baseline
Query!
Assessment method [33]
0
0
The POEM is a 7-item self-assessment questionnaire that assesses disease symptoms on a 5-point scale; 0 (no days) to 4 (every day in the last week). The sum of the 7 items gives the total POEM score of 0 (absent disease) to 28 (very severe). Higher scores indicated more severe disease and poor quality of life.
Query!
Timepoint [33]
0
0
Baseline to Week 36
Query!
Secondary outcome [34]
0
0
Proportion of participants with rescue medication use
Query!
Assessment method [34]
0
0
Query!
Timepoint [34]
0
0
Baseline to Week 36
Query!
Secondary outcome [35]
0
0
Time to onset of effect on PP-NRS as measured by proportion of participants with an improvement (reduction) in PP-NRS by =4
Query!
Assessment method [35]
0
0
The PP-NRS is a validated single item 0-10 numeric rating scale assessing peak pruritus (itch) associated with AD with 0 = no itch and 10 = worst itch imaginable.
Query!
Timepoint [35]
0
0
Baseline to Week 36
Query!
Secondary outcome [36]
0
0
Percentage of TCS/TCI free days
Query!
Assessment method [36]
0
0
Query!
Timepoint [36]
0
0
Baseline to Week 36
Query!
Secondary outcome [37]
0
0
Percentage of participants who experienced Treatment-Emergent Adverse Events (TEAEs), experienced Treatment-Emergent Serious Adverse Events (TESAEs) and/or Treatment-Emergent Adverse Events of Special Interest (AESI)
Query!
Assessment method [37]
0
0
Query!
Timepoint [37]
0
0
Baseline to Week 52
Query!
Secondary outcome [38]
0
0
Serum amlitelimab concentrations
Query!
Assessment method [38]
0
0
Query!
Timepoint [38]
0
0
Baseline to Week 52
Query!
Secondary outcome [39]
0
0
Incidence of antidrug antibodies (ADAs) of amlitelimab
Query!
Assessment method [39]
0
0
Query!
Timepoint [39]
0
0
Baseline to Week 52
Query!
Secondary outcome [40]
0
0
Time to onset of effect on vIGA-AD as measured by proportion of participants with vIGA-AD 0 (clear) or 1 (almost clear) and a reduction from baseline =2 during the 36-week treatment period
Query!
Assessment method [40]
0
0
The vIGA-AD is an Investigator-completed assessment scale used to determine severity of AD and clinical response to treatment. It is based on a 5-point scale, ranging from 0 (clear) to 4 (severe).
Query!
Timepoint [40]
0
0
Baseline to Week 36
Query!
Secondary outcome [41]
0
0
Time to onset of effect on EASI as measured by proportion of participants reaching a 75% reduction from baseline in EASI score during the 36-week treatment period
Query!
Assessment method [41]
0
0
The EASI is an Investigator-assessed validated tool used to measure the extent (area) and severity of AD. Total score ranges from 0 to 72 with a higher score indicating increased extent and severity of AD. EASI-75 is 75% reduction from baseline in EASI score.
Query!
Timepoint [41]
0
0
Baseline to Week 36
Query!
Eligibility
Key inclusion criteria
* Participants must be 12 years of age (when signing informed consent form)
* Diagnosis of AD for at least 1 year (defined by the American Academy of Dermatology Consensus Criteria)
* Documented history prior to screening visit of inadequate response to a biologic AD medication or an oral JAKi therapy.
* v-IGA-AD of 3 or 4 at baseline visit
* EASI score of 16 or higher at baseline
* AD involvement of 10% or more of BSA at baseline
* Weekly average of daily PP-NRS of = 4 at baseline visit.
* Able and willing to comply with requested study visits and procedures
* Body weight =25 kg
Query!
Minimum age
12
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
Participants are excluded from the study if any of the following criteria apply:
* Skin co-morbidity that would adversely affect the ability to undertake AD assessments
* Known history of or suspected significant current immunosuppression
* Any malignancies or history of malignancies prior to baseline (with the exception of non-melanoma skin cancer excised and cured >5 years prior to baseline)
* History of solid organ or stem cell transplant
* Any active or chronic infection including helminthic infection requiring systemic treatment within 4 weeks prior to baseline
* Positive for human immunodeficiency virus (HIV), Hepatitis B or hepatitis C at screening visit
* Having active tuberculosis (TB), latent TB, a history of incompletely treated TB, suspected extrapulmonary TB infection, or who are at high risk of contracting TB
* Having received any of the specified therapy within the specified timeframe(s) prior to the baseline visit
* In the Investigator's opinion, any clinically significant laboratory results or protocol specified laboratory abnormalities at screening
* History of hypersensitivity or allergy to any of the excipients or investigational medicinal product (IMP)
The above information is not intended to contain all considerations relevant to a potential participation in a clinical trial
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Recruiting
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
29/02/2024
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
30/06/2026
Query!
Actual
Query!
Sample size
Target
249
Query!
Accrual to date
Query!
Final
Query!
Recruitment in Australia
Recruitment state(s)
VIC
Query!
Recruitment hospital [1]
0
0
Investigational Site Number : 0360008 - Melbourne
Query!
Recruitment hospital [2]
0
0
Investigational Site Number : 0360006 - Melbourne
Query!
Recruitment postcode(s) [1]
0
0
3002 - Melbourne
Query!
Recruitment postcode(s) [2]
0
0
3004 - Melbourne
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Alabama
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Arizona
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Arkansas
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
California
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Colorado
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Florida
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Illinois
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Indiana
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Kentucky
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
Louisiana
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
Michigan
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
Nebraska
Query!
Country [13]
0
0
United States of America
Query!
State/province [13]
0
0
New Jersey
Query!
Country [14]
0
0
United States of America
Query!
State/province [14]
0
0
New Mexico
Query!
Country [15]
0
0
United States of America
Query!
State/province [15]
0
0
New York
Query!
Country [16]
0
0
United States of America
Query!
State/province [16]
0
0
Oregon
Query!
Country [17]
0
0
United States of America
Query!
State/province [17]
0
0
Pennsylvania
Query!
Country [18]
0
0
United States of America
Query!
State/province [18]
0
0
South Carolina
Query!
Country [19]
0
0
United States of America
Query!
State/province [19]
0
0
Texas
Query!
Country [20]
0
0
United States of America
Query!
State/province [20]
0
0
Utah
Query!
Country [21]
0
0
United States of America
Query!
State/province [21]
0
0
Virginia
Query!
Country [22]
0
0
United States of America
Query!
State/province [22]
0
0
Washington
Query!
Country [23]
0
0
United States of America
Query!
State/province [23]
0
0
Wisconsin
Query!
Country [24]
0
0
United States of America
Query!
State/province [24]
0
0
Wyoming
Query!
Country [25]
0
0
Argentina
Query!
State/province [25]
0
0
Santa Fe
Query!
Country [26]
0
0
Argentina
Query!
State/province [26]
0
0
Buenos Aires
Query!
Country [27]
0
0
Argentina
Query!
State/province [27]
0
0
Córdoba
Query!
Country [28]
0
0
Brazil
Query!
State/province [28]
0
0
Bahia
Query!
Country [29]
0
0
Brazil
Query!
State/province [29]
0
0
Rio Grande Do Sul
Query!
Country [30]
0
0
Brazil
Query!
State/province [30]
0
0
São Paulo
Query!
Country [31]
0
0
Canada
Query!
State/province [31]
0
0
Alberta
Query!
Country [32]
0
0
Canada
Query!
State/province [32]
0
0
Ontario
Query!
Country [33]
0
0
Canada
Query!
State/province [33]
0
0
Saskatchewan
Query!
Country [34]
0
0
Chile
Query!
State/province [34]
0
0
Reg Metropolitana De Santiago
Query!
Country [35]
0
0
China
Query!
State/province [35]
0
0
Changchun
Query!
Country [36]
0
0
China
Query!
State/province [36]
0
0
Guangzhou
Query!
Country [37]
0
0
China
Query!
State/province [37]
0
0
Hangzhou
Query!
Country [38]
0
0
China
Query!
State/province [38]
0
0
Nanyang
Query!
Country [39]
0
0
China
Query!
State/province [39]
0
0
Ningbo
Query!
Country [40]
0
0
China
Query!
State/province [40]
0
0
Shanghai
Query!
Country [41]
0
0
China
Query!
State/province [41]
0
0
Shenyang
Query!
Country [42]
0
0
China
Query!
State/province [42]
0
0
Wuhan
Query!
Country [43]
0
0
China
Query!
State/province [43]
0
0
Xi An
Query!
Country [44]
0
0
France
Query!
State/province [44]
0
0
Bordeaux
Query!
Country [45]
0
0
France
Query!
State/province [45]
0
0
Clermont-ferrand
Query!
Country [46]
0
0
France
Query!
State/province [46]
0
0
Créteil
Query!
Country [47]
0
0
France
Query!
State/province [47]
0
0
Lille
Query!
Country [48]
0
0
France
Query!
State/province [48]
0
0
Paris
Query!
Country [49]
0
0
France
Query!
State/province [49]
0
0
Rouen
Query!
Country [50]
0
0
France
Query!
State/province [50]
0
0
Saint Pierre
Query!
Country [51]
0
0
Germany
Query!
State/province [51]
0
0
Berlin
Query!
Country [52]
0
0
Germany
Query!
State/province [52]
0
0
Blankenfelde-mahlow
Query!
Country [53]
0
0
Germany
Query!
State/province [53]
0
0
Dresden
Query!
Country [54]
0
0
Germany
Query!
State/province [54]
0
0
Lübeck
Query!
Country [55]
0
0
Germany
Query!
State/province [55]
0
0
Witten
Query!
Country [56]
0
0
Greece
Query!
State/province [56]
0
0
Athens
Query!
Country [57]
0
0
Greece
Query!
State/province [57]
0
0
Thessaloniki
Query!
Country [58]
0
0
Israel
Query!
State/province [58]
0
0
Be'er Sheva
Query!
Country [59]
0
0
Israel
Query!
State/province [59]
0
0
Ramat Gan
Query!
Country [60]
0
0
Israel
Query!
State/province [60]
0
0
Tel Aviv
Query!
Country [61]
0
0
Italy
Query!
State/province [61]
0
0
Napoli
Query!
Country [62]
0
0
Italy
Query!
State/province [62]
0
0
Torino
Query!
Country [63]
0
0
Italy
Query!
State/province [63]
0
0
Chieti
Query!
Country [64]
0
0
Italy
Query!
State/province [64]
0
0
Modena
Query!
Country [65]
0
0
Italy
Query!
State/province [65]
0
0
Perugia
Query!
Country [66]
0
0
Japan
Query!
State/province [66]
0
0
Kanagawa
Query!
Country [67]
0
0
Japan
Query!
State/province [67]
0
0
Osaka
Query!
Country [68]
0
0
Japan
Query!
State/province [68]
0
0
Tochigi
Query!
Country [69]
0
0
Japan
Query!
State/province [69]
0
0
Tokyo
Query!
Country [70]
0
0
Japan
Query!
State/province [70]
0
0
Hiroshima
Query!
Country [71]
0
0
Korea, Republic of
Query!
State/province [71]
0
0
Gyeonggi-do
Query!
Country [72]
0
0
Korea, Republic of
Query!
State/province [72]
0
0
Incheon-gwangyeoksi
Query!
Country [73]
0
0
Korea, Republic of
Query!
State/province [73]
0
0
Seoul-teukbyeolsi
Query!
Country [74]
0
0
Mexico
Query!
State/province [74]
0
0
Nuevo León
Query!
Country [75]
0
0
Mexico
Query!
State/province [75]
0
0
Veracruz
Query!
Country [76]
0
0
Netherlands
Query!
State/province [76]
0
0
Rotterdam
Query!
Country [77]
0
0
Netherlands
Query!
State/province [77]
0
0
Utrecht
Query!
Country [78]
0
0
Poland
Query!
State/province [78]
0
0
Dolnoslaskie
Query!
Country [79]
0
0
Poland
Query!
State/province [79]
0
0
Lubelskie
Query!
Country [80]
0
0
Poland
Query!
State/province [80]
0
0
Mazowieckie
Query!
Country [81]
0
0
Poland
Query!
State/province [81]
0
0
Pomorskie
Query!
Country [82]
0
0
Saudi Arabia
Query!
State/province [82]
0
0
Riyadh
Query!
Country [83]
0
0
Spain
Query!
State/province [83]
0
0
Barcelona [Barcelona]
Query!
Country [84]
0
0
Spain
Query!
State/province [84]
0
0
Madrid
Query!
Country [85]
0
0
Spain
Query!
State/province [85]
0
0
Sevilla
Query!
Country [86]
0
0
Spain
Query!
State/province [86]
0
0
Alicante
Query!
Country [87]
0
0
Taiwan
Query!
State/province [87]
0
0
Kaohsiung City
Query!
Country [88]
0
0
Taiwan
Query!
State/province [88]
0
0
Taipei City
Query!
Country [89]
0
0
Taiwan
Query!
State/province [89]
0
0
Taipei
Query!
Country [90]
0
0
Taiwan
Query!
State/province [90]
0
0
Taoyuan City
Query!
Country [91]
0
0
Turkey
Query!
State/province [91]
0
0
Gaziantep
Query!
Country [92]
0
0
Turkey
Query!
State/province [92]
0
0
Istanbul
Query!
Country [93]
0
0
United Arab Emirates
Query!
State/province [93]
0
0
Abu Dhabi
Query!
Country [94]
0
0
United Kingdom
Query!
State/province [94]
0
0
Bristol, City Of
Query!
Country [95]
0
0
United Kingdom
Query!
State/province [95]
0
0
Devon
Query!
Country [96]
0
0
United Kingdom
Query!
State/province [96]
0
0
England
Query!
Country [97]
0
0
United Kingdom
Query!
State/province [97]
0
0
Hampshire
Query!
Country [98]
0
0
United Kingdom
Query!
State/province [98]
0
0
North Yorkshire
Query!
Country [99]
0
0
United Kingdom
Query!
State/province [99]
0
0
Nottinghamshire
Query!
Country [100]
0
0
United Kingdom
Query!
State/province [100]
0
0
Liverpool
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Query!
Name
Sanofi
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
This is a parallel group, Phase 3, multinational, multicenter, randomized, double-blind, placebo-controlled, 3-arm study for treatment of participants diagnosed with moderate-to-severe AD on background TCS who have had inadequate response to prior biologic or oral JAKi therapy. The purpose of this study is to measure the efficacy and safety of treatment with amlitelimab solution for subcutaneous (SC) injection compared with placebo in participants with moderate-to-severe AD aged 12 years and older on background TCS and have had an inadequate response to prior biologic or an oral JAKi therapy. Study details include: At the end of the treatment period, participants will have the option to enter the Long-Term Safety Study LTS17367 (RIVER-AD). The study duration will be up to 56 weeks for participants not entering the long-term safety study (LTS17367 \[RIVER-AD\]) including a 2 to 4-week screening, a 36-week randomized double-blind period, and a 16-week safety follow-up. The study duration will be up to 40 weeks for participants entering the long-term safety study (LTS17367 \[RIVER-AD\]) including a 2 to 4-week screening and a 36-week randomized double-blind period. The total treatment duration will be up to 36 weeks. The total number of visits will be up to 13 visits (or 12 visits for those entering the long-term safety study LTS17367 \[RIVER-AD\] study).
Query!
Trial website
https://clinicaltrials.gov/study/NCT06241118
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Trial Transparency email recommended (Toll free for US & Canada)
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
800-633-1610
Query!
Fax
0
0
Query!
Email
0
0
[email protected]
Query!
Contact person for scientific queries
Data sharing statement
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
No documents have been uploaded by study researchers.
Results not provided in
https://clinicaltrials.gov/study/NCT06241118
Download to PDF